BIOPHARMA CREDIT PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 17, 2021

National Storage Mechanism | Additional information

RNS Number : 2951C

BioPharma Credit PLC

17 June 2021

BIOPHARMA CREDIT PLC

(THE "COMPANY")

RESULT OF ANNUAL GENERAL MEETING

The Company is pleased to announce that, at the Annual General Meeting held today, all resolutions put to the meeting were passed on a show of hands.

As set out in the circular to shareholders dated 4 June 2021, Resolutions 9 and 10, in connection with the appointment of the auditor, were withdrawn. The AGM was subsequently adjourned and will be reconvened on 24 June 2021 at 1:05 p.m. at the offices of Herbert Smith Freehills LLP, Exchange Hose, Primrose Street, London, EC2A 2EG following the conclusion of the General Meeting convened for the same day at 1.00 p.m. Resolution 1, in connection with the approval of the annual report and financial statements for the year ended 31 December 2020 will be proposed at the adjourned AGM.

The proxy votes received in relation to these resolutions were as follows:

Resolutions	Votes For	%	Votes Against	%	Votes at Chairman's Discretion	Votes Withheld
1: To receive and accept the annual report and financial statements	Adjourned
2: To approve the Directors' Remuneration Report	613,712,139	99.99	15,334	0.01	0	669
3: To approve the Directors' Remuneration Policy	613,712,139	99.99	15,334	0.01	0	669
4: To re-elect Harry Hyman as a Director	613,728,142	100	0	0	0	0
5: To re-elect Colin Bond as a Director	613,728,142	100	0	0	0	0
6: To re-elect Duncan Budge as a Director	613,728,142	100	0	0	0	0
7: To re-elect Stephanie Léouzon as a Director	613,728,142	100	0	0	0	0
8: To elect Rolf Soderstrom as a Director	613,727,803	100	0	0	0	339
9: To appoint Ernst & Young LLP as Auditor to the Company	Withdrawn
10: To authorise the Directors to determine the remuneration of the Auditor	Withdrawn
11: To approve the Company's dividend payment policy	613,728,142	100	0	0	0	0
12: To authorise the Company to make market purchases of ordinary shares	613,728,142	100	0	0	0	0
13: To authorise the Company to hold general meetings on 14 clear days' notice	613,710,808	99.99	17,334	0.01	0	0

A copy of resolutions 12 and 13 has been submitted to the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

17 June 2021

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 500

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGDKOBBQBKDKAD